Related Experiment Video
Updated: Jun 23, 2026
05:10
Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
Published on: December 11, 2016
[Original drugs or generics: how to choose?]
Summary
Generic drugs may not be interchangeable with original antiepileptic drugs, potentially destabilizing epilepsy treatment. A database is needed to guide medical professionals on drug interchangeability for patient safety.
Area of Science:
- Pharmacology
- Clinical Pharmacy
- Drug Regulation
Context:
- Interchangeability of original and generic drugs is a critical issue in healthcare.
- Pharmacokinetic trials for drug registration do not always guarantee therapeutic equivalence.
- Antiepileptic drugs require careful management due to epilepsy's prevalence, long-term treatment needs, and narrow therapeutic index.
Purpose:
- To critically evaluate the interchangeability of original and generic drug preparations.
- To assess whether pharmacokinetic bioequivalence trials adequately predict therapeutic effect similarity.
- To highlight the risks associated with generic antiepileptic drug use in epilepsy management.
Summary:
- Analysis of current literature suggests that pharmacokinetic trials for drug registration may not confirm similar therapeutic effects between original drugs and generics.
- The use of generic antiepileptic drugs warrants extreme caution due to potential destabilization of the disease course.
- A comprehensive database on drug interchangeability is proposed for the medical community.
Impact:
- Findings emphasize the need for a cautious approach when prescribing generic antiepileptic drugs.
- Highlights potential risks to patient health and treatment efficacy.
- Advocates for improved resources to support informed clinical decision-making regarding drug interchangeability.
More Related Videos
Related Concept Videos
01:17Drug Nomenclature
During the development of a new pharmaceutical, the manufacturer initially assigns a code name to the drug. Once approved, the drug receives a United States Adopted Name (USAN)—a generic, nonproprietary designation. Upon being listed in the United States Pharmacopeia, this nonproprietary name becomes the drug's official name. Additionally, the manufacturer assigns a proprietary name or trademark, which serves as the brand name under which the drug is marketed. It is worth noting that the same...
01:28Drug Products: Biologics, Biosimilars and Interchangeables
Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
01:22Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence
Generic intravenous (IV) drugs are considered bioequivalent to their branded counterparts due to their 100% bioavailability upon administration. However, variations in stability among different drug products can significantly influence their therapeutic performance, even if they are pharmaceutically equivalent.Cefuroxime, a prophylactic antimicrobial, is often used as a single-dose IV injection for patients undergoing coronary artery bypass grafting surgery. A 3 g dose typically provides...
01:19Pharmaceutical Alternatives: Excipients and Impurities-Related Therapeutic Nonequivalence
Pharmaceutical products contain more than just the active drug; they also contain various excipients such as binders, solubilizers, stabilizers, preservatives, and other elements. In some cases, impurities or contaminants might be present. Traditionally, quality control in pharmaceuticals has primarily focused on the analysis of the active drug, often overlooking the impact of these additional components. The recent issue with heparin contamination by over-sulfated chondroitin sulfate, a...
01:09Bioequivalence of Drugs: Drugs with Multiple Indications
The concept of therapeutic equivalence (TE) in drugs with multiple indications is complex. A generic drug may be therapeutically equivalent to a brand-name product for one specific indication, but this doesn't necessarily mean it's equivalent for all other indications. Evidence of TE in one patient group and bioequivalence shown in healthy volunteers can support—but not confirm—TE for other indications. However, definitive proof requires individual clinical studies for each indication due to...
01:27Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence
Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...